Flt3 - OmicsDI

Show results for

Unknown (1904)
Genomics (771)
Transcriptomics (656)
Multiomics (179)
Proteomics (72)
Other (17)
Methylation profiling (15)
Genomic (3)
Clinical (3)
Metabolomics (2)

Organisms

Homo sapiens (466)
Mus musculus (360)
Schizosaccharomyces pombe (56)
Oryza sativa Indica Group (56)
Sinorhizobium meliloti BL225C (56)
Sus scrofa domesticus (56)
Ostreococcus tauri (56)
Saccharomyces cerevisiae (56)
Staphylococcus aureus (56)
Rattus norvegicus (56)
Escherichia coli (56)
Candida albicans (56)
Cyanophora paradoxa (56)
Entamoeba histolytica (56)
Physcomitrium patens (56)
Methylohalobius crimeensis 10Ki (56)
Homo sapiens (56)
Lotus japonicus (56)
Marchantia polymorpha (56)
Shigella flexneri (56)
Ctenopharyngodon idella (56)
Danio rerio (56)
Allexis (56)
Streptococcus agalactiae (1)
Staphylococcus aureus (1)
unidentified plasmid (1)
Salmo salar (1)
Canis lupus familiaris (1)
synthetic construct (1)
Mus (1)

Organisms

Homo sapiens (275)
Mus musculus (274)
Salmo salar (1)
Canis lupus familiaris (1)

Repository

ENA (636)
geo (430)
biostudies-arrayexpress (351)
LINCS (182)
pride (56)
EGA (37)
MassIVE (13)
dbGaP (3)
ExpressionAtlas (2)
iProX (1)
jPOST (1)
MetaboLights (1)
MetabolomicsWorkbench (1)
PanoramaPublic (1)

Tissue

Cell culture (16)
Blood cell (15)
Blood (13)
Bone marrow (6)
Leukocyte (5)
Monocyte (5)
Cell suspension culture (4)
B cell (4)
Dendritic cell (3)
Epithelial cell (3)
Myeloid cell (2)
AML cells (1)
Acute lymphoblastic leukemia cell line (1)
Conventional dendritic cell (1)
Myeloblast (1)
Microglial cell (1)
Kidney cell (1)
Microglia (1)
Macrophage (1)
Brain (1)
Stem cell (1)
Spleen (1)
Primary cell (1)
Lung (1)
Permanent cell line cell (1)

Disease

Acute leukemia (27)
Acute myeloid leukemia (9)
Avian influenza (3)
Influenza (3)
Acute promyelocytic leukemia (2)
Colorectal Neoplasms (2)
Disease free (2)
Invasive pituitary adenoma (1)
Acute Myeloid Leukemia (1)
Megakaryoblastic leukemia (1)
Normal (1)
Pancreatic Neoplasms (1)
Myeloma (1)
Disease of metabolism (1)
Obesity (1)
Lymphoma (1)

Technology Type

KINOMEscan (182)
Fluorescence intensity (179)
Mass Spectrometry (57)
Shotgun proteomics (30)
Affinity purification coupled with mass spectrometry proteomics (9)
Bottom-up proteomics (7)
Data-dependent acquisition (5)
Top-down proteomics (5)
Illumina HiSeq 2000 (4)
Gel-based experiment (4)
QPCR (3)
SRM/MRM (2)
ILLUMINA, Illumina HiSeq 1000 (1)
Illumina MiSeq (1)
Mass spectrometry (1)
ESI (1)
All-ion fragmentation (1)
Data-independent acquisition (1)

Instrument Platform

Illumina NovaSeq 6000 (13)
Illumina HiSeq 2000 (9)
Flow Cytometer (4)
Illumina HiSeq 2500 (4)
Q Exactive Plus (4)
NA (3)
Illumina HiSeq 4000 (3)
Orbitrap Fusion Lumos (3)
Thermomixer (2)
Illumina NovaSeq X (2)
NextSeq 550 (2)
LTQ Orbitrap Elite (2)
TimsTOF Pro (2)
Q Exactive (2)
LTQ Orbitrap Velos (2)
Real-time PCR Thermal Cycler (1)
SMARTerTM Ultra Low RNA Kit (1)
Flow cytometer (1)
NextSeq 2000 (1)
Illumina MiSeq (1)
Illumina HiSeq 1500 (1)
Illumina HiSeq 3000 (1)
NextSeq 500 (1)
Orbitrap Fusion (1)
Q Exactive HF (1)
Liquid Chromatography MS - positive - reverse phase (1)
Liquid Chromatography MS - negative - reverse phase (1)

Publication Date

2015 (169)
2016 (126)
2023 (75)
2021 (56)
2012 (54)
2022 (53)
2025 (50)
2014 (50)
2011 (45)
2017 (43)
2010 (43)
2013 (41)
2008 (40)
2026 (39)
2024 (38)
2018 (29)
2020 (25)
2019 (21)
2009 (21)
2007 (10)
2006 (4)
2005 (4)
2004 (2)

Metabolite Name

TG(20:5/O-18:0/22:6) (1)
1-Cyclopropyl-3-(3-(5-(morpholinomethyl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazol-4-yl)urea (1)
MG(0:0/18:1/0:0) (1)
Thioacetamide-S-oxide (1)
Therafectin (1)
3-Methyl-2-thioxoimidazolidin-4-one (1)
N-Formyl-DL-methionine (1)
7-[(2-Benzyl-3-sulfanylpropanoyl)amino]heptanoic acid (1)
Ethoxybenzyl diethylenetriamine (1)
E-10 devinylajoene (1)
Maleimide-thiol (1)
Sodium dimethyldithiocarbamate (1)
Copanlisib (1)
Caffeic acid 3-O-glucuronide (1)
19,20-(E)-Vallesamine (1)
DG(18:1-O/a-17:0/0:0) (1)
Menadiol sodium diphosphate (1)
(S)-3-(2-Methylphenoxy)propane-1,2-diol (1)
1-naphthoate (1)
Immepip (1)
SM(d18:2/PGE1) (1)
Sulfamethoxypyridazine (1)
D-Desthiobiotin (1)
Tasidotin (1)
Eugenyl benzoate (1)
Kaempferide 3-glucuronide (1)
THIEPIN (1)
Kaempferide 3-glucoside-7-rhamnoside (1)
Mangiferin 6'-gallate (1)
1,2 Dipalmitoylphosphatidylcholine (1)

First Public Date

2014 (99)
2023 (79)
2024 (62)
2021 (62)
2025 (52)
2022 (50)
2026 (45)
2020 (37)
2018 (35)
2019 (29)
2017 (26)
2015 (26)
2016 (25)
2013 (8)
2012 (1)

Modification

Not available (1)

Study status

Completed (2)
Terminated (1)

Study type

Transcription profiling by array (229)
RNA-seq of coding RNA (41)
ChIP-seq (18)
Methylation profiling by array (7)
Methylation profiling by high throughput sequencing (6)
Comparative genomic hybridization by array (5)
Other (5)
MicroRNA profiling by array (5)
RNA-seq of coding RNA from single cells (4)
Unknown experiment type (3)
ChIP-chip by tiling array (3)
Cell line - High-throughput sequencing (3)
Transcription profiling by RT-PCR (3)
ATAC-seq (3)
RNA-seq of non coding RNA (3)
Interventional (3)
Animal - High-throughput sequencing (2)
RNAi profiling by array (2)
Genotyping by array (2)
Baseline (1)
Differential (1)
Animal - One-color microarray (1)
Human - High-throughput sequencing (1)
DNA-seq (1)
CUT&RUN (1)
RNA-seq of total RNA (1)

Release Date

2022 (257)
2021 (194)
2023 (189)
2025 (184)
2020 (168)
2024 (137)
2019 (135)
2016 (134)
2015 (127)
2018 (126)
2014 (102)
2017 (95)
2012 (78)
2010 (70)
2011 (68)
2013 (61)
2008 (47)
2026 (25)
2009 (20)
2007 (16)
2006 (15)
2005 (5)
2004 (1)
1999 (1)

Lab affiliation

Institute of Biochemistry II, Faculty of Medicine, Goethe University, Frankfurt, Germany (4)
Amsterdam UMC, Vrije Universiteit Amsterdam, Medical Oncology, Cancer Center Amsterdam, OncoProteomics Laboratory, Amsterdam, Netherlands (3)
BCMP, Harvard Medical School, Boston, USA Cancer Biology, Dana-Farber Cancer Institute, Boston, USA (2)
CRUK - Scotland Institute - Switchback Rd, Bearsden, Glasgow G61 1BD - United Kingdom (2)
Cambridge Stem Cell Institute, Cambridge, United Kingdom, CB2 0AW (1)
University of Newcastle, Callaghan, NSW, Australia (1)
Dept. Cellular Molecular Pharmacology, University of San Francisco (UCSF), USA (1)
Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Switzerland Department for BioMedical Research (DBMR), University of Bern, Switzerland (1)
University Medical Center Schleswig-Holstein, Clinic for Hematology and Oncology,Lübeck, Germany (1)
School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, and Cancer Research Program, Hunter Medical Research Institute, NSW, 2308, Australia (1)
Novo Nordisk Foundation Center for Protein Research University of Copenhagen Faculty of Health and Medical Sciences Blegdamsvej 3B København N (1)
Department of Biotechnology and Biomedicine, Technical University of Denmark, Lyngby, Denmark (1)
Englander Institute of Precision Medicine Professor Radiation Oncology Professor Physiology and Biophysics Weill Cornell Medicine 1300 York Avenue Room E215 New York, NY 10065 tel 646-962-2160 (1)
Centre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London (1)
INSERM U1016, Institut Cochin, CNRS UMR8104, Paris, France; Université Paris Descartes, Faculté de Médecine Sorbonne Paris Cité, Paris, France; Equipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Paris, France. (1)
Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London (1)
Department of Biochemistry, Western University (1)
Collège de France, Oncologie Cellulaire et Moléculaire, PSL University, INSERM UMR 1050, CNRS UMR 7241, INSERM UMR 944, CNRS UMR 7212, Université de Paris, IRSL, Hôpital St. Louis Paris France (1)
Dept. of Bioloy, University of Rome Tor Vergata (1)
Department of Biosciences & Medical Biology, Paris Lodron University of Salzburg, Austria. (1)
Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada (1)
1School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, NSW, 2308, Australia 2 Precision Medicine Research Program, Hunter Medical Research Institute, New Lambton Heights, NSW, 2305, Australia (1)
Leibniz-Institut fur Analytische Wissenschaften - ISAS - e.V. (1)
Leukemia Department, MD Anderson Cancer Center, Houston, TX 77030 (1)
Dept. Cellular Molecular Pharmacology, University of California - San Francisco (UCSF), USA (1)
Associate Professor Director of Graduate Studies BMBB Biochemistry, Molecular Biology, and Biophysics 7-140 MCB 420 Washington Avenue SE Minneapolis, MN 55455 (1)
Department of Biology, University of Rome Tor Vergata, Via delle Ricerca Scientifica 1, 00133 Rome, Italy (1)
Division of Haematology, Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China. (1)
Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA; Department of Pathology, University of Massachusetts Medical School, Worcester, MA, USA. (1)
Evotec, Martinsried, Germany (1)

Location

China (3)

Keyword

Famitinib (3)
GEPNET (1)
Phase II (1)
CRC (1)

Previous page
1 / 363
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 363
Next page

Sort by:

Relevance

Page size

Effect of kinase inhibitors on FLT3-ITD AML cell metabolomes

Not available

ORGANISM(S): Mus musculus

ST000055 | MetabolomicsWorkbench

FLT3 activation cooperates with MLL-AF4 fusion gene to abrogate the hematopoietic specification of human ESCs

MLL-AF4 is a hallmark genomic aberration which arises prenatally in high-risk infant acute lymphoblastic leukemia (ALL). In human embryonic stem cells (hESCs), MLL-AF4 skewed hemato-endothelial specification but was not sufficient for transformation. Additional cooperating genetic insults seem requi...

ORGANISM(S): Homo sapiens

2013-06-04 | E-GEOD-40103 | biostudies-arrayexpress

Molecular variability of FLT3/ITD mutants and their impact on the differentiation program of 32D cells

FLT3 is the most frequently mutated gene in AML â€“ up to 40% of AML harbor an activating mutation within FLT3 gene. Though AML is a relatively rare disease, such a high mutability rate, as observed with FLT3 gene, is striking. To elucidate the molecular background of this phenomenon, we have establ...

ORGANISM(S): Mus musculus

2010-04-08 | E-GEOD-12766 | biostudies-arrayexpress

Gene expression analysis of WT and Flt3-ITD multipotent progenitors

FLT3-ITDs Introduce a Myeloid Differentiation and Transformation Bias in Lympho-myeloid Multipotent Progenitors WT multipotent progenitors were compared with FLT3-ITD multipotent progenitors

ORGANISM(S): Mus musculus

2014-05-16 | E-GEOD-35805 | biostudies-arrayexpress

de novo childhood AML patients and FLT3 mutations.

This data set was used to study FLT3 wild type and mutants in childhood AML samples from the Pediatric Oncology Group Study 9421. Abstract: Fms-like tyrosine kinase 3 (FLT3) mutations are associated with unfavorable outcomes in children with acute myeloid leukemia (AML). We used DNA microarrays to i...

ORGANISM(S): Homo sapiens

2006-01-06 | E-GEOD-3986 | biostudies-arrayexpress

GRP94 rewires and buffers the FLT3-ITD signaling network and promotes survival of acute myeloid leukemic stem cells

Internal tandem duplications in the tyrosine kinase receptor FLT3 (FLT3-ITD) are among the most common lesions in acute myeloid leukemia (AML) and there exists a need for new forms of treatment. Using ex vivo drug sensitivity screening, we found that FLT3-ITD+ patient cells are particularly sensitiv...

ORGANISM(S): Homo sapiens (Human)

2020-09-02 | PXD009423 | Pride

FLT3 gene-expression signature in normal karyotype AML

Acute myeloid leukemia with normal karyotype (NK-AML) represents a cytogenetic grouping with intermediate prognosis but substantial molecular and clinical heterogeneity. Within this subgroup, presence of FLT3 (FMS-like tyrosine kinase 3) internal tandem duplication (ITD) mutation predicts less favo...

ORGANISM(S): Homo sapiens

2008-02-27 | E-GEOD-8043 | biostudies-arrayexpress

Transcription profiling of mouse FLT3+/CD11b+ Dendritic cell (DC) progenitor

FLT3+/CD11b+ Dendritic cell (DC) progenitor was amplified in vitro from mouse bone marrow.

ORGANISM(S): Mus musculus

2008-06-15 | E-GEOD-692 | biostudies-arrayexpress

Transcription profiling of Acute Promyelocytic Leukemia samples from patients with wild type FLT3 or FLT3 mutations

In this series we described the gene expression profiles of 18 APL patients using a high density DNA-oligonucleotide microarray (Agilent) representing about 20.000 genes demonstrating the presence of a very uniform expression pattern of APL cases among which two mainly types of gene profiles were re...

ORGANISM(S): Homo sapiens

2008-05-07 | E-GEOD-2550 | biostudies-arrayexpress

Gene Expression Profiling of the MLL-AF4 and Flt3 tyrosine kinase domain (TKD) genes in 32Dc cell

The tumorigenesis capacity of MLL-AF4 alone is insufficient for causing leukemia. Based on the finding that an Flt3 gene mutation in the tyrosine kinase domain (TKD) was observed in approximately 15% of MLL leukemia, we investigated synergistic leukemogenesis effects of the two genes in vitro. In a ...

ORGANISM(S): Mus musculus

2009-03-31 | E-GEOD-14236 | biostudies-arrayexpress

Previous page
1 / 363
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 363
Next page

Sort by:

Relevance

Page size

3622 Results

Show results for

Organisms

Organisms

Repository

Tissue

Disease

Technology Type

Instrument Platform

Publication Date

Metabolite Name

First Public Date

Modification

Study status

Study type

Release Date

Lab affiliation

Location

Tags

Keyword

OmicsDI is part of the ELIXIR infrastructure

Tweets